{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:31:26Z","timestamp":1791203486540,"version":"4.2.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1932,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.jacc.2008.03.003","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T17:50:55Z","timestamp":1208454655000},"page":"1564-1572","source":"Crossref","is-referenced-by-count":72,"title":["Lipid-Altering Efficacy and Safety of Ezetimibe\/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia"],"prefix":"10.1016","volume":"51","author":[{"given":"John R.","family":"Guyton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Greg","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Polis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2008.03.003_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2008.03.003_bib2","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2006.04.026","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib3","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2008.03.003_bib4","first-page":"1711","article-title":"Present-day uses of niacin: effects on lipid and non-lipid parameters","volume":"11","author":"Sanyal","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacc.2008.03.003_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2007.02.004","article-title":"Should both HDL-C and LDL-C be targets for lipid therapy?","volume":"1","author":"Brown","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2008.03.003_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOL.0b013e3282364add","article-title":"Niacin in cardiovascular prevention: mechanisms, efficacy, and safety","volume":"18","author":"Guyton","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2008.03.003_bib7","unstructured":"Niaspan [product insert]. N. Chicago, IL: Abbott Laboratories, 2007."},{"key":"10.1016\/j.jacc.2008.03.003_bib8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2008.03.003_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2008.03.003_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/174182670200900607","article-title":"Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy","volume":"9","author":"Duvall","year":"2002","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.jacc.2008.03.003_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (The ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1520-037X.2004.3217.x","article-title":"Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia","volume":"7","author":"Capuzzi","year":"2004","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2008.03.003_bib16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2008.03.003_bib17","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2\u2014a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2008.03.003_bib18","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2008.03.003_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jacc.2008.03.003_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2008.03.003_bib21","first-page":"360","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1974","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2008.03.003_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2008.03.003_bib23","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2008.03.003_bib24","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2008.03.003_bib25","series-title":"Vytorin","year":"2003"},{"key":"10.1016\/j.jacc.2008.03.003_bib26","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2008.03.003_bib27","first-page":"S4","article-title":"Standards of Medical Care","volume":"30","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2008.03.003_bib28","author":"O'Riordan"},{"key":"10.1016\/j.jacc.2008.03.003_bib29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5414\/CPP44633","article-title":"Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation","volume":"44","author":"Cefali","year":"2006","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.jacc.2008.03.003_bib30","unstructured":"Merck\/Schering Plough Pharmaceutical analysis of data from IMS Health. Whitehouse Station, NJ: NPA Monthly, 2007."},{"key":"10.1016\/j.jacc.2008.03.003_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)","volume":"93","author":"Zhao","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ahj.2007.04.035","article-title":"Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study","volume":"154","author":"Zhao","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2008.03.003_bib36","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjcard.2006.10.064","article-title":"Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study","volume":"99","author":"Rosseb\u00f8","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2008.03.003_bib37","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"63","author":"Baigent","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jacc.2008.03.003_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Design and Rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome","author":"Cannon","year":"2008","journal-title":"Am Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109708008528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109708008528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T09:14:23Z","timestamp":1557479663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109708008528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":36,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0735109708008528"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2008.03.003","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}